2008
Current status of Japanese HIV-infected patients with coagulation disorders : coinfection with both HIV and HCV
TATSUNAMI, Shinobu, Junichi MIMAYA, Akira SHIRATA, Jiří ZELINKA, Ivanka HOROVÁ et. al.Základní údaje
Originální název
Current status of Japanese HIV-infected patients with coagulation disorders : coinfection with both HIV and HCV
Název česky
Současný stav japonských HIV pacientů s poruchou koagulace: koinfekce HIV i HCV
Autoři
TATSUNAMI, Shinobu (392 Japonsko), Junichi MIMAYA (392 Japonsko), Akira SHIRATA (392 Japonsko), Jiří ZELINKA (203 Česká republika), Ivanka HOROVÁ (203 Česká republika, garant), Jugo HANAI (392 Japonsko), Yukata NISHINA (392 Japonsko), Katsumi OHIRA (392 Japonsko) a Masashi TAKI (392 Japonsko)
Vydání
International Journal of Hematology, Japonsko, Springer, 2008, 0925-5710
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Japonsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 1.283
Kód RIV
RIV/00216224:14310/08:00027284
Organizační jednotka
Přírodovědecká fakulta
UT WoS
000259910200012
Klíčová slova anglicky
Hemophiliacs; Coagulation disorders; HIV; HCV; Survival; Surveillance
Štítky
Příznaky
Recenzováno
Změněno: 23. 6. 2009 10:26, Mgr. Jiří Zelinka, Dr.
V originále
We herein report on the current status of Japanese HIV-positive patients with coagulation disorders, primarily hemophilia, based on the national survey of 31 May 2006. The total number of registered patients was 1,431 (Hemophilia A 1,086; Hemophilia B 325; von Willebrand disease 8; others 12), and 604 of these patients were deceased by 31 May 2006. The survival rate after the beginning of 1983 was evaluated by the Kaplan-Meier method. The total number of surviving patients was 827, and the survival rate on 31 May 2006 was 55.7 +- 1.4%. Among the 827 surviving patients, HCV antibody was observed in 740, was negative in 16, and was not reported in 71 patients. Thus, the prevalence of HCV infection was 98% in the surviving patients based on the presence of HCV antibody. Among the 604 deceased patients, liver disease was reported as a cause of death in 149 cases (25%), and infection with HCV was reported as the possible cause of liver disease in 120 cases (20%). After 1997, 63 cases among the subtotal of 148 deaths had critical hepatic disease that originated from HCV infection, which accounted for 43% of the subtotal. The cumulative rate of patients who received interferon therapy was 32%. Interferon therapy should be prescribed more frequently to HIV-positive patients with coagulation disorders in order to realize the survival benefits, although clinicians should be aware of side effects and toxicities.
Česky
Je zdo podám výzkum stavu japonských HIV pacientů s poruchou koagulace.
Návaznosti
LC06024, projekt VaV |
|